AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Nighttime GERD Hits Many.
Gastroesophageal reflux disease is about as prevalent at night as it is during the day, affecting 79% of American adults with heartburn.
That finding emerged from a study presented by Dr. Reza Shaker of the Medical College of Wisconsin, Milwaukee, at the annual Digestive Disease Week.
Of 1,000 Americans who reported having heartburn symptoms within the prior week or who were current users of GERD medication, the reported prevalence of daytime heartburn was 85%, and the prevalence of nighttime heartburn was 79% according to a Gallop telephone survey.
Half of those surveyed said their nighttime GERD symptoms were worse than their daytime symptoms. Two-thirds of those with nighttime GERD said that their symptoms kept them up three or more times a week, and 70% said that their symptoms woke them ...
- Schering-Plough To Make 20-mg Dose.
- Magazine article from: BIOWORLD Today Deal, Santarus Gets As Much As $80m In Otc Zegerid October 23, 2006 700+ words
...Schering-Plough will develop, make and sell Zegerid at the 20-mg dose, which likely will require "some type of clinical trials...Doctors write more than 95 percent of prescriptions for the 40-mg dose, Proehl said, a trend "in line with other PPI drugs available...
- Safety and pharmacokinetics of famciclovir single 1500 mg dose in adolescents...
- Magazine article from: Journal of Drugs in Dermatology June 1, 2009 700+ words
...study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis...pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose. Inclusion criteria is as follows: Outpatient males or females...
- FDA ADVISES DOCTORS TO STOP USING 100 MG DOSE OF MANOPLAX
- Press release article from: PR Newswire April 26, 1993 700+ words
WASHINGTON, April 26 /PRNewswire/ -- The Food and Drug Administration today recommended that at the present time doctors stop using a 100 milligram per day dose of the new heart drug Manoplax (flosequinan). This recommendation is based on the results of a controlled trial comparing Manoplax and a
- WYETH-AYERST LABORATORIES' LODINE(R) (ETODOLAC) RECEIVES NEW RHEUMATOID...
- Press release article from: Business Wire July 2, 1996 700+ words
RADNOR, PaBUSINESS WIREJuly 2, 1996--Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), announced today that Lodine(R) (etodolac), a nonsteroidal anti- inflammatory drug (NSAID), is now indicated for the treatment of rheumatoid arthritis. At the same time the
- Sitaxsentan proves effective in pulmonary arterial hypertension: the phase III...
- Magazine article from: Family Practice News Goldman, Bruce August 15, 2005 700+ words
SAN DIEGO -- An investigational drug, sitaxsentan, improved exercise capacity and World Health Organization functional class in patients with pulmonary arterial hypertension in a phase III trial, Robyn J. Barst, M.D., reported at the 100th International Conference of the American Thoracic Society.
- Bristol-Myers Squibb Announces U.S. Food And Drug Administration Approval Of...
- Press release article from: PR Newswire April 14, 2003 700+ words
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved Glucophage(R) XR (metformin HCl extended release tablets) 750 mg tablet, a new dosage strength of one of the leading type 2 diabetes therapies. Glucophage XR, which was launched in October
- Aeolus Pharmaceuticals, Inc. Announces Optimistic AEOL 10150 Phase 1 Clinical...
- Press release article from: PR Newswire March 29, 2005 700+ words
RESEARCH TRIANGLE PARK, N.C., March 29 /PRNewswire-FirstCall/ -- Aeolus Pharmaceuticals, Inc. (BULLETIN BOARD: AOLS.OB) , a developer of a potential new class of disease-modifying compounds that have evidenced efficacy in pre-clinical models of central nervous system diseases and disorders and
- Best practices in: recognition and management of nighttime reflux...
- Magazine article from: Family Practice News June 1, 2007 700+ words
...Multiple studies have demonstrated that nighttime GERD has a substantial adverse impact on...until recently obscured the impact of nighttime GERD. A survey of 1,000 GERD patients...but still substantial, rates of nighttime GERD symptoms. A community-based study...
Source: HighBeam Research, Nighttime GERD Hits Many.